Mechanism of immune escape of human osteosarcoma cells through abnormal expressions of Fas and Fas ligand.

人骨肉瘤细胞通过Fas和Fas配体表达异常的免疫逃逸机制。

基本信息

  • 批准号:
    11670198
  • 负责人:
  • 金额:
    $ 1.98万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

Osteosarcoma cells frequently metastasize to the lungs. Metastatic process is composed of several different steps. Of them, escape from the immune surveilance system is one of the essential ability for osteosarcoma cells to obtain. Recent studies have reported that some carcinoma cells could escape from cytotoxic T-lymphocytes through loss of function of Fas receptor and might counter-attack them through gain of function of Fas ligand (Fas L). We investigated status and function of Fas and Fas L in human osteosarcomas to clarify the molecular mechanism of immune escape working in human osteosarcoma.1. Expressions of Fas and Fas L were demonstrated in established three human osteosarcoma cell lines (HOS, OST and Saos2) and three osteosarcma tissues both at message ad protein levels using RT-PCR and Western blot. No structural abnormality was detected by direct sequencing.2. Osteosarcoma tissues showed Fas of both membrane-bounded and soluble-form. Soluble Fas was a predominant form of F … More as produced in established osteosarcoma cell lines and only OST expressed not only soluble but membrane-bounded form, that was confirmed by immunofluorescent study. Immunohistochemical studies demonstrated expression of Fas in 17 of 22 osteosarcomas. Eleven osteosarcomas (65%) were membrane-type and 6 (35%) in the cytoplasm.3. Fas ligand expressed in both established osteosarcoma cells and tissues was membrane-bounded and no soluble Fas L was detected at all. Immunohistochemistry disclosed overexpression of Fas L in 17 (85%) of 20 cases. No significant correlation was detected between the expression of Fas L and clinicopatholgical parameters including stage, chemosensitivity and prognosis. Status of Fas L expression was not correlated to number of apoptosis of cytotoxic T-lymphocytes infiltrated in the tumor tissues demonstrated by TUNEL-CD8 staining.4. Function of Fas L expressed in osteosarcoma tissues and established osteosarcoma cell lines was demonstrated by the osbervation of apoptosis-induction in Fas-sensitive Jurkat cells which were incuvated on the frozen sections of osteosarcoma tissues or on monolayer of established osteosarcoma cell lines. The apoptosis was significantly inhibited by the incubation with neutralizing anti-Fas L antibody (NOK1), indicating that the apoptosis occurred via Fas/Fas L passway.5. Adriamycin-induced cardiaomyopathy was apoptotic mechanism via overexpession of Fas on the myocardium.These results showed that status of Fas and Fas L might reflect imprtant phenomena in human osteosarcoma and that osteosarcoma cells could escape from immune surveilance through loss of Fas and gain of FasL.Modulation of the Fas and Fas L expressions may be one of new therapeutic strategies against osteosarcomas. Less
骨肉瘤细胞经常转移到肺部。转移过程由几个不同的步骤组成。其中,逃离免疫监视系统是骨肉瘤细胞获得的基本能力之一。最近的研究报道,一些癌细胞可以通过Fas受体功能的丧失而逃离细胞毒性t淋巴细胞,并可能通过Fas配体功能的获得(Fas L)来进行反击。我们研究了Fas和Fas L在人骨肉瘤中的地位和功能,以阐明免疫逃逸在人骨肉瘤中的分子机制。利用RT-PCR和Western blot技术,在已建立的3种人骨肉瘤细胞系(HOS、OST和Saos2)和3种骨肉瘤组织中证实了Fas和Fas L在信息和蛋白水平上的表达。直接测序未发现结构异常。骨肉瘤组织中Fas呈膜结合型和可溶性两种形态。可溶性Fas是F的主要形式,在已建立的骨肉瘤细胞系中产生,只有OST不仅表达可溶性Fas,而且表达膜结合形式,免疫荧光研究证实了这一点。免疫组化研究显示22例骨肉瘤中有17例表达Fas。11例(65%)骨肉瘤为膜型,6例(35%)为细胞质型。Fas配体在已建立的骨肉瘤细胞和组织中的表达都是膜结合的,完全没有检测到可溶性Fas L。免疫组化显示Fas L过表达17例(85%)。Fas L的表达与分期、化疗敏感性、预后等临床病理指标无明显相关性。TUNEL-CD8染色结果显示,Fas - L的表达状态与肿瘤组织浸润的细胞毒性t淋巴细胞凋亡数量无关。Fas L在骨肉瘤组织和已建立的骨肉瘤细胞系中表达的功能是通过观察Fas敏感的Jurkat细胞的凋亡诱导,这些细胞分别培养在骨肉瘤组织的冷冻切片或已建立的骨肉瘤细胞系的单层上。中和性抗Fas L抗体(NOK1)孵育可明显抑制细胞凋亡,表明细胞凋亡是通过Fas/Fas L通路发生的。阿霉素诱导心肌病的凋亡机制是通过心肌细胞Fas的过度表达。这些结果表明,Fas和FasL的状态可能反映了人骨肉瘤的重要现象,骨肉瘤细胞可以通过Fas的缺失和FasL的获得来逃避免疫监视。调节Fas和Fas L的表达可能是治疗骨肉瘤的新策略之一。少

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tsuneyuki Nakamura et al.: "Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats.In vivo study."Circulation. 102. 572-578 (2000)
Tsuneyuki Nakamura 等人:“Fas 介导的阿霉素诱导的大鼠心肌病细胞凋亡。体内研究。”循环。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsuneyuki Nakamura et al.: "Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats. In vivo study."Circulation. 102. 572-578 (2000)
Tsuneyuki Nakamura 等人:“Fas 介导的阿霉素诱导的大鼠心肌病细胞凋亡。体内研究。”循环。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

UEDA Yoshimichi其他文献

UEDA Yoshimichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('UEDA Yoshimichi', 18)}}的其他基金

Is sphingolipid of the cell membrane involved in invasion and metastasis of non-adenocarcinoma of the lung?
细胞膜鞘脂是否参与肺非腺癌的侵袭和转移?
  • 批准号:
    18K07002
  • 财政年份:
    2018
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An approach to free independence based on mutual information
基于互信息的自由独立方法
  • 批准号:
    16K13762
  • 财政年份:
    2016
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Is sphingolipid of the cell membrane involved in invasion and metastasis of adenocarcinoma of the lung?
细胞膜鞘脂是否参与肺腺癌的侵袭和转移?
  • 批准号:
    26460442
  • 财政年份:
    2014
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on von Neumann algebras, free probability and non-commutative function spaces
冯诺依曼代数、自由概率和非交换函数空间的研究
  • 批准号:
    24540214
  • 财政年份:
    2012
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement and their roles of aquaporins in the metastasis and drug-resistance of bone and soft tissue sarcomas
水通道蛋白在骨软组织肉瘤转移和耐药中的参与及其作用
  • 批准号:
    22590323
  • 财政年份:
    2010
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on free probability and operator algebras
自由概率与算子代数研究
  • 批准号:
    20540213
  • 财政年份:
    2008
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of activation mechanism of HMGA2 gene and its regulating gene-pathways in the progression of lung cancer
HMGA2基因在肺癌进展中的激活机制及其调控基因通路分析
  • 批准号:
    19590370
  • 财政年份:
    2007
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of activated gene network in the microenvironment of lung cancer-invasion front.
肺癌侵袭前沿微环境激活基因网络分析
  • 批准号:
    17590320
  • 财政年份:
    2005
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Expression profiling of genes involved in tumor - host stroma cell interaction in the metastasis of human fibrosarcoma cell (HT1080)
人纤维肉瘤细胞(HT1080)转移中涉及肿瘤-宿主基质细胞相互作用的基因的表达谱
  • 批准号:
    15590322
  • 财政年份:
    2003
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of gene expressions involved in cancer-host cells cross talk at the invasion front of nonsmall cell lung cancer
非小细胞肺癌侵袭前沿癌症与宿主细胞串扰相关基因表达分析
  • 批准号:
    13670192
  • 财政年份:
    2001
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Elucidation of tumor development mechanism by immune escape mechanism through metabolic reprogramming of anticancer drug-resistant cancer
通过抗癌药物耐药性癌症的代谢重编程的免疫逃逸机制阐明肿瘤发生机制
  • 批准号:
    23K18344
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Detailed Elucidation of Cancer Immune Escape Mechanisms Focusing on Regulatory T Cells in the Microenvironment of Cholangiocarcinoma
详细阐明胆管癌微环境中调节性T细胞的癌症免疫逃逸机制
  • 批准号:
    23K15088
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The impact of immune escape on the epidemiology and evolutionary dynamics of the COVID-19 pandemic in Yucatan, Mexico
免疫逃逸对墨西哥尤卡坦半岛 COVID-19 大流行的流行病学和进化动态的影响
  • 批准号:
    10741899
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
A new concept in evolutionary epidemiology, meta-R0, on immune escape of pathogens.
进化流行病学中的一个新概念,meta-R0,关于病原体的免疫逃逸。
  • 批准号:
    23H02527
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Prediction of viral evolution trajectories on antigenic space using a stochastic immune escape model
使用随机免疫逃逸模型预测抗原空间上的病毒进化轨迹
  • 批准号:
    23K18150
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Novel immune-escape uricase for treatment of hyperuricemia
治疗高尿酸血症的新型免疫逃逸尿酸酶
  • 批准号:
    10696609
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Drug discovery of next-generation circular mRNA vaccine platform targeting tumor immune escape mechanism
针对肿瘤免疫逃逸机制的下一代环状mRNA疫苗平台的药物发现
  • 批准号:
    22KK0288
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Explore hepatitis B virus preS2 mutants as immune escape mutants
探索乙型肝炎病毒preS2突变体作为免疫逃逸突变体
  • 批准号:
    10572374
  • 财政年份:
    2022
  • 资助金额:
    $ 1.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了